SCHEMBL6531199

SCHEMBL6531199

Cc1ccc2c(c1)/C(=C/c1ccc3cn[nH]c3c1)C(=O)N2

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
RET P07949 4/20 0.51
PDGFRB P09619 1/20 0.51
PDPK1 O15530 1/20 0.51
MAPT P10636 4/20 0.50
ALDH1A1 P00352 1/20 0.50
TGM2 P21980 1/20 0.45
PLK4 O00444 1/20 0.44
APP P05067 3/20 0.44
LRRK2 Q5S007 2/20 0.44
SNCA P37840 1/20 0.44
PSEN1 P49768 2/20 0.43
PSEN2 P49810 2/20 0.43
APH1B Q8WW43 2/20 0.43
NCSTN Q92542 2/20 0.43
APH1A Q96BI3 2/20 0.43
PSENEN Q9NZ42 2/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6531204 1.00 MEN1 (0.52) MEN1KMT2ARETPDGFRBPDPK1
SCHEMBL12848343 1.00 MEN1 (0.52) MEN1KMT2ARETPDGFRBPDPK1
SCHEMBL3721457 0.85 APP (0.58) RETPDGFRBPDPK1MAPTPLK4
SCHEMBL3721460 0.85 APP (0.58) RETPDGFRBPDPK1MAPTPLK4
SCHEMBL6525514 0.85 RPS6KA3 (0.54) MEN1KMT2APDGFRBPLK4
SCHEMBL6525211 0.85 LRRK2 (0.62) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL6526040 0.85 RPS6KA3 (0.54) MEN1KMT2APDGFRBPLK4
SCHEMBL6525507 0.85 RPS6KA3 (0.54) MEN1KMT2APDGFRBPLK4
SCHEMBL3711781 0.85 PLK4 (0.62) MEN1KMT2ARETPDGFRBTGM2
SCHEMBL3711780 0.85 PLK4 (0.62) MEN1KMT2ARETPDGFRBTGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 MEN1 3149/4885KMT2A 1713/4885RET 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.